Use of misoprostol on an outpatient basis for postdate pregnancy

Kipikasa, J.H.; Adair, C.D.; Williamson, J.; Breen, J.M.; Medford, L.K.; Sanchez-Ramos, L.
February 2005
International Journal of Gynecology & Obstetrics;Feb2005, Vol. 88 Issue 2, p108
Academic Journal
journal article
Objective: Within the obstetric community, several studies suggest that cervical ripening and labor induction after 40 weeks' gestation leads to improved maternal and neonatal outcomes. The most effective drug regimen to safely promote labor has not been determined.Method: Forty-nine subjects followed in an outpatient obstetrical clinic with pregnancies of at least 40 weeks' gestation, and an unfavorable Bishop score were assigned randomly to receive oral misoprostol 50 or 25 microg every 3 days for a maximum of three doses.Results: Twenty-three subjects received misoprostol 25 microg and 26 received 50 microg. The mean interval (+/-standard deviation) from start of cervical ripening to delivery was 2.4 days +/-0.3 vs. 3.9 days +/-0.7 for the 50 and 25 microg groups (P<0.05). No adverse events were noted. However, due to small sample size, less frequent adverse events may be missed. Type II errors cannot be excluded.Conclusion: In the prevention of postdate pregnancy, outpatients use of oral misoprostol 50 microg appears to result in earlier delivery, as compared to 25 microg.


Related Articles

  • Intracervical misoprostol and prostaglandin E2 for labor induction Chang, Y.-K.; Chen, W.-H.; Yu, M.-H.; Liu, H.-S. // International Journal of Gynecology & Obstetrics;Jan2003, Vol. 80 Issue 1, p23 

    Objectives: To compare the safety and efficacy of misoprostol with PGE2 for induction of labor by intracervical administration. Methods: Eighty-six women with indications for labor induction at term were randomly assigned to two groups. Each woman received either 50 μg of misoprostol or 0.5...

  • Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol Meydanli, M.M.; Çalışkan, E.; Burak, F.; Narin, M.A.; Atmaca, R.; Calişkan, E // International Journal of Gynecology & Obstetrics;Jun2003, Vol. 81 Issue 3, p249 

    Objectives: To compare the effectiveness of 25 μg vs. 50 μg of intravaginal misoprostol for cervical ripening and labor induction beyond 41 weeks’ gestation. Methods: The study population consisted of 120 women not in active labor with a gestational age >41 weeks, singleton...

  • Use of Oral Misoprostol for Cervical Priming before Hysteroscopy: A Randomized Comparison of Two Dosages. Kesrouani, Assaad; Maalouf, Samer; Mansour, Fersan; Attieh, Elie // Gynecologic & Obstetric Investigation;Jul2016, Vol. 81 Issue 4, p333 

    Objective: The study aims to compare the safety and effectiveness of 200 and 400 µg of oral misoprostol for cervical priming before hysteroscopy.Methods: A double-blinded randomized study included 70 patients scheduled for hysteroscopy in a Lebanese University...

  • Cervical priming with sublingual misoprostol vs. 15-methyl-prostaglandin F2α prior to surgical abortion Vimala, N.; Mittal, S.; Dadhwal, V. // International Journal of Gynecology & Obstetrics;Feb2005, Vol. 88 Issue 2, p134 

    Abstract: Objective: To compare the efficacy and tolerability of sublingual misoprostol with those of intramuscular 15-methyl-prostaglandin F2α (15-M-PG F2α) for cervical dilation prior to vacuum aspiration (VA) in first-trimester pregnancy termination. Methods: Sixty pregnant women...

  • Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Groopman, Jerome E.; Gottlieb, Michael S.; Goodman, Jesse; Mitsuyasu, Ronald T.; Conant, Marcus A.; Prince, Harry; Fahey, John L.; Derezin, Marvin; Weinstein, Wilfred M.; Casavante, Conrad; Rothman, John; Rudnick, Seth A.; Volberding, Paul A.; Groopman, J E; Gottlieb, M S; Goodman, J; Mitsuyasu, R T; Conant, M A; Prince, H; Fahey, J L // Annals of Internal Medicine;May84, Vol. 100 Issue 5, p671 

    In a randomized prospective study we tested the toxicity and efficacy of recombinant alpha-2 interferon in the treatment of Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. High doses (50 X 10(6) U/m2 body surface area, intravenously) or low doses (1 X 10(6) U/m2,...

  • Drotaverine hydrochloride for augmentation of labor Singh, K.C.; Jain, P.; Goel, N.; Saxena, A. // International Journal of Gynecology & Obstetrics;Jan2004, Vol. 84 Issue 1, p17 

    Objectives: To study the use of drotaverine hydrochloride for acceleration of labor and relief of labor pains. Methods: In this double-blind placebo-controlled randomized study, 100 primigravidas in uncomplicated spontaneous labor at term were given drotaverine hydrochloride or placebo...

  • Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Oranje, Arnold P.; Chosidow, Olivier; Sacchidanand, Sarvajnamurthy; Todd, Gail; Singh, Krishan; Scangarella, Nicole; Shawar, Ribhi; Twynholm, Monique; TOC100224 Study Team // Dermatology (10188665);Dec2007, Vol. 215 Issue 4, p331 

    Background: Retapamulin is a novel pleuromutilin antibacterial developed for topical use. Objective: To compare the efficacy and safety of retapamulin ointment, 1% (twice daily for 5 days), with sodium fusidate ointment, 2% (3 times daily for 7 days), in impetigo....

  • A comparison of labor induction by oral and vaginal misoprostol Pongsatha, S.; Vijittrawiwat, A.; Tongsong, T. // International Journal of Gynecology & Obstetrics;Feb2005, Vol. 88 Issue 2, p140 

    No abstract available.

  • Misoprostol Prior to Diagnostic Office Hysteroscopy in the Subgroup of Patients with No Risk Factors for Cervical Stenosis: A Randomized Double Blind Placebo-Controlled Trial. Fouda, Usama M.; Elsetohy, Khaled A.; Elshaer, Hesham S.; Hammad, Bahaa Eldin M.; Shaban, Mona M.; Youssef, Mohamed A.; Hashem, Ahmed T.; Attia, Ahmed H. // Gynecologic & Obstetric Investigation;Sep2018, Vol. 83 Issue 5, p455 

    Aims: To assess the effectiveness of vaginal misoprostol in minimizing the pain perceived by patients with no risk factors for cervical stenosis (i.e., parous women of reproductive age who have no history of cesarean section or cervical surgery) during diagnostic office...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics